Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects who voluntarily sign the informed consent.~* Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies.~Exclusion Criteria:~* Subject is using or will use investigational medications, except as approved by Abbott.~* Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 20 mg drug and ABT-335
- B (Type: ACTIVE_COMPARATOR): 40 mg drug and ABT 335
- C (Type: ACTIVE_COMPARATOR): 40 mg drug and ABT-335

Based on this trial design, predict the completion outcome and termination type (if applicable).